Ucinnost anti-tNF-alpha léciv v bĕzné klinické praxi a náklady na tato léciva
[Effectiveness of TNF antagonists in routine clinical practice and costs]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article, Review
PubMed
19227955
- MeSH
- Adalimumab MeSH
- Cost-Benefit Analysis MeSH
- Antirheumatic Agents economics therapeutic use MeSH
- Etanercept MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Immunoglobulin G economics therapeutic use MeSH
- Infliximab MeSH
- Humans MeSH
- Antibodies, Monoclonal economics therapeutic use MeSH
- Receptors, Tumor Necrosis Factor therapeutic use MeSH
- Arthritis, Rheumatoid drug therapy economics MeSH
- Tumor Necrosis Factor-alpha antagonists & inhibitors MeSH
- Check Tag
- Humans MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Review MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Adalimumab MeSH
- Antirheumatic Agents MeSH
- Etanercept MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Immunoglobulin G MeSH
- Infliximab MeSH
- Antibodies, Monoclonal MeSH
- Receptors, Tumor Necrosis Factor MeSH
- Tumor Necrosis Factor-alpha MeSH
A comparison of effectiveness of TNF antagonists adalimumab, infliximab and etanercept in the treatment of rheumatoid arthritis (RA) was made, which was derived from studies provided abroad based on routine clinical practice. The calculation of cost-effectiveness of each TNF antagonist for Czech Republic was made on the basis of Dutch DREAM registry of patients with RA (Kiewit et al, 2008). The prices of therapy of all three TNF antagonists are similar in the first year of treatment of patients with average weight, in the second year the price of infliximab is lower, but only in the case of patients where the doses do not reach 4 amp. of infliximab. Clinical effectiveness was evaluated in DAS28 and HAQ units. Cost-effectiveness of all TNF antagonists was similar, when 2 amp. of infliximab per dose phycician considered sufficient, but when patients were given higher doses of infliximab the trend to lower cost-effectiveness of infliximab compared to adalimumab and etanercept was observed.
